Polysubstituted indan-1-ol systems for the prophylaxis or...

Details Polysubstituted indan-1-ol systems for the prophylaxis or... Polysubstituted indan-1-ol systems for the prophylaxis or...

2002-08-29

2004-02-03

Vollano, Jean F. (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Sulfur, selenium or tellurium compound

C514S706000, C514S602000, C568S034000, C564S340000, C562S041000, C562S405000

Reexamination Certificate

active

06686397

ABSTRACT:

RELATED APPLICATION DATA
The instant application takes priority from DE 10142659.3 filed Aug. 31, 2001 which is incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to polysubstituted indan-1-ol compounds and their physiologically acceptable salts and physiologically functional derivatives for the prophylaxis or treatment of obesity.
2. Description of the Related Art
WO 97/20806 discloses cyclopentyl-substituted indan-1-ol derivatives as antiinflammatory substances.
SUMMARY OF THE INVENTION
In a preferred embodiment, the invention provides compounds which can be used for reducing weight in mammals and which are suitable for preventing and treating obesity. The instant compounds s have a therapeutically utilizable anorectic action.
In another preferred embodiment, the invention also provides a pharmaceutical composition comprising an effective amount of a compound of formula I. The pharmaceutical composition may also comprise one or more active compounds suitable for reducing weight or for the treatment of obesity. The instant composition may also comprise one or more compounds suitable for treatment of other disorders.
In another preferred embodiment, the instant invention provides a method for the treating obesity, comprising administering to a subject in need thereof, an effective amount of a compound according to formula.
In another preferred embodiment, the instant invention provides a method of reducing weight in a mammal, comprising administering to said mammal an effective amount of a compound of formula I.
Additional objects, features and advantages of the invention will be set forth in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The objects, features and advantages of the invention may be realized and obtained by means of the instrumentalities and combinations particularly pointed out in the appended claims.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The invention relates to compounds of the formula (I)
in which
R1, R2, R3, R4 independently of one another are H, F, Cl, Br, I, CN, N
3
, NO
2
, OH, O(C
1
-C
8
)-alkyl, O(C
3
-C
8
)-cycloalkyl, O—CH
2
-phenyl, O-phenyl, O—CO—(C
1
-C
8
)-alkyl, O—CO—(C
3
-C
8
)-cycloalkyl, where in the alkyl radicals up to seven hydrogen atoms may be replaced by fluorine;
S(O)
0-2
(C
1
-C
8
)-alkyl, S(O)
0-2
(C
3
-C
8
)-cycloalkyl, where in the alkyl radicals up to seven hydrogen atoms may be replaced by fluorine; NH
2
, NH—(C
1
-C
8
)-alkyl, NH—(C
3
-C
8
)-cycloalkyl, N[(C
1
-C
8
)-alkyl]
2
, N[(C
3
-C
8
)-cycloalkyl]
2
, NH—CO—(C
1
-C
8
)-alkyl, NH—CO—(C
3
-C
8
)-cycloalkyl;
SO
3
H; SO
2
—NH
2
, SO
2
—NH—(C
1
-C
8
)-alkyl, SO
2
—NH—(C
3
-C
8
)-cycloalkyl; SO
2
—(C
1
-C
6
)-alkyl; NH—SO
2
—NH
2
; NH—SO
2
—(C
1
-C
8
)-alkyl, NH—SO
2
—(C
3
-C
8
)-cycloalkyl; O—CH
2
—COOH, O—CH
2
—CO—O(C
1
-C
8
)-alkyl, COOH, COO(C
1
-C
8
)-alkyl, CO—O—(C
3
-C
8
)-cycloalkyl, CO—NH
2
, CO—NH(C
1
-C
8
)-alkyl, CO—N[(C
1
-C
8
)-alkyl]
2
;
(C
1
-C
8
)-alkyl, (C
3
-C
8
)cycloalkyl, (C
2
-C
8
)-alkenyl, (C
2
-C
8
)-alkynyl, where in the alkyl, alkenyl and alkynyl groups one to seven hydrogen atoms may be replaced by fluorine;
or one hydrogen may be replaced by OH, OC(O)CH
3
, O—CH
2
—Ph, NH
2
, NH—CO—CH
3
or N(COOCH
2
Ph)
2
;
phenyl, 1- or 2-naphthyl,
5-tetrazolyl, 1-[(C
1
-C
6
)-alkyl]-5-tetrazolyl, 2-[(C
1
-C
6
)-alkyl]-5-tetrazolyl,
1-imidazolyl,
1- or 4-[1,2,4]-triazolyl,
2- or 3-thienyl,
2- or 3-furyl,
2-, 3- or 4-pyridyl,
2-, 4- or 5-oxazolyl,
3-, 4- or 5-isoxazolyl,
2-, 4- or 5-thiazolyl,
3-, 4- or 5-isothiazolyl,
where the aryl radical or heterocycle may be substituted up to two times by
F, Cl, Br, CN,
OH, (C
1
-C
4
)-alkyl, CF
3
, O—(C
1
-C
4
)-alkyl,
S(O)
0-2
(C
1
-C
6
)-alkyl, NH
2
, NH—SO
2
—(C
1
-C
4
)-alkyl;
COOH, CO—O—(C
1
-C
4
)-alkyl, CO—NH
2
and where in the alkyl groups one to seven hydrogen atoms may be replaced by fluorine; or
R2 and R3 together form the radical —O—CH
2
—O—;
X is S, SO, SO
2
;
Y is (CH
2
)
p
, where p may be 0, 1, 2 or 3;
R5 is (C
1
-C
18
)-alkyl, (C
3
-C
8
)-cycloalkyl,
where in the alkyl groups up to seven hydrogen atoms may be replaced by fluorine;
(CH
2
)
1-6
—COOH, (CH
2
)
1-6
—COO—(C
1
-C
6
)-alkyl, (CH
2
)
1-6
—CONH
2
;
CH
2
—CH(NHR10)-COR11, where R10 may be H or C(O)—(C
1
-C
6
)-alkyl and R11 may be OH, O—(C
1
-C
6
)-alkyl or NH
2
;
phenyl, 1- or 2-naphthyl, biphenyl or a heterocyclic radical, where the rings or ring systems are in each case substituted up to three times by
F, Cl, Br, I, CN, OH, O(C
1
-C
8
)-alkyl, O(C
3
-C
8
)-cycloalkyl, O—CO—(C
1
-C
8
)-alkyl, O—CO—(C
3
-C
8
)-cycloalkyl, S(O)
0-2
(C
1
-C
8
)-alkyl, S(O)
0-2
(C
3
-C
8
)-cycloalkyl, NH
2
, NH—(C
1
-C
8
)-alkyl, NH—(C
3
-C
8
)-cycloalkyl, N[(C
1
-C
8
)-alkyl]
2
, N[(C
3
-C
8
)-cycloalkyl]
2
, NH—CO—(C
1
-C
8
)-alkyl, NH—CO—(C
3
-C
8
)-cycloalkyl; SO
3
H, SO
2
—NH
2
, SO
2
—NH—(C
1
-C
8
)-alkyl, SO
2
—NH—(C
3
-C
8
)-cycloalkyl; NH—SO
2
—NH
2
; NH—SO
2
—(C
1
-C
8
)-alkyl, NH—SO
2
—(C
3
-C
8
)-cycloalkyl; O—CH
2
—COOH, O—CH
2
—CO—O(C
1
-C
8
)-alkyl, COOH, CO—O(C
1
-C
8
)-alkyl, CO—O—(C
3
-C
8
)-cycloalkyl, CO—NH
2
, CO—NH(C
1
-C
8
)-alkyl, CO—N[(C
1
-C
8
)-alkyl]
2
;
(C
1
-C
8
)-alkyl, (C
3
-C
8
)-cycloalkyl, where in the alkyl groups in each case one to seven hydrogen atoms may be replaced by fluorine;
R6 is (CH
2
)
0-6
—R9, (CH
2
)
0-6
—COOH, (CH
2
)
0-6
—COO—(C
1
-C
6
)-alkyl, (CH
2
)
0-6
—CONH
2
, (CH
2
)
0-6
—CH(NHR15)-COR16, F, Cl, Br, CN, (C
1
-C
18
)-alkyl, (C
3
-C
4
)-cycloalkyl, (C
6
-C
8
)-cycloalkyl, where in the alkyl radicals or cycloalkyl radicals up to seven hydrogen atoms may be replaced by fluorine;
R15 is H, C(O)—(C
1
-C
6
)-alkyl;
R16 is OH, O—(C
1
-C
6
)-alkyl, NH
2
,
R7 is (CH
2
)
0-4
—R12, H, (C
1
-C
12
)-alkyl, (C
3
-C
4
)-cycloalkyl, (C
6
-C
8
)-cycloalkyl, COO(C
1
-C
6
)-alkyl, COO(C
3
-C
8
)-cycloalkyl, where in the alkyl radicals or cycloalkyl radicals up to seven hydrogen atoms may be replaced by fluorine;
R8 is (CH
2
)
0-4
—R14, (C
1
-C
12
)-alkyl, (C
3
-C
4
)-cycloalkyl, (C
6
-C
8
)-cycloalkyl, where in the alkyl or cycloalkyl radicals up to seven hydrogen atoms may be replaced by fluorine atoms;
R9, R12, R14 independently of one another are
phenyl, 1- or 2-naphthyl, biphenyl, or a heterocyclic radical, where the rings or ring systems are in each case substituted up to three times by
F, Cl, Br, I, CN, OH, O(C
1
-C
8
)-alkyl, O(C
3
-C
8
)-cycloalkyl, O—CO—(C
1
-C
8
)-alkyl, O—CO—(C
3
-C
8
)-cycloalkyl, S(O)
0-2
(C
1
-C
8
)-alkyl, S(O)
0-2
(C
3
-C
8
)-cycloalkyl, NH
2
, NH—(C
1
-C
8
)-alkyl, NH—(C
3
-C
8
)-cycloalkyl, N[(C
1
-C
8
)-alkyl]
2
, N[(C
3
-C
8
)-cycloalkyl]
2
, NH—CO—(C
1
-C
8
)-alkyl, NH—CO—(C
3
-C
8
)-cycloalkyl, SO
3
H; SO
2
—NH
2
, SO
2
—NH—(C
1
-C
8
)-alkyl, SO
2
—NH—(C
3
-C
8
)-cycloalkyl, NH—SO
2
—NH
2
; NH—SO
2
—(C
1
-C
8
)-alkyl, NH—SO
2
—(C
3
-C
8
)-cycloalkyl; O—CH
2
—COOH, O—CH
2
—CO—O(C
1
-C
8
)-alkyl, COOH, CO—O(C
1
-C
8
)-alkyl, CO—O—(C
3
-C
8
)-cycloalkyl, CO—NH
2
, CO—NH(C
1
-C
8
)-alkyl, CO—N[(C
1
-C
8
)-alkyl]
2
;
(C
1
-C
8
)-alkyl, (C
3
-C
8
)-cycloalkyl, where in the alkyl groups in each case one to seven hydrogen atoms may be replaced by fluorine;
and their physiologically acceptable salts.
In a preferred embodiment, the invention provides compounds of the formula I in which
R1, R2, R3, R4 independently of one another are H, F, Cl, Br, N
3
, O(C
1
-C
8
)-alkyl, (C
1
-C
8
)-alkyl and where in the alkyl groups one to seven hydrogen atoms may be replaced by fluorine;
where in each case at least one of the radicals R1, R2, R3 and R4 is different from hydrogen;
X is S, SO, SO
2
;
Y is (CH
2
)
p
, where p may be 0, 1, 2 or 3;
R5 is (C
1
-C
18
)-alkyl, (C
3
-C
4
)-cycloalkyl, (C
6
-C
8
)-cycloalkyl,
where in the alkyl groups up to seven hydrogen atoms may be replaced by fluorine;
(CH
2
)
1-6
—COOH, (CH
2
1-6
—COO—(C
1
-C
6
)-alkyl, (CH
2
)
1-6
—CONH
2
;
CH
2
—CH(NHR10)-COR11, where R10 may be H or C(O)—(C
1
-C
6
)-alkyl and

Affiliated with

Also associated with

Rating

Polysubstituted indan-1-ol systems for the prophylaxis or... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polysubstituted indan-1-ol systems for the prophylaxis or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polysubstituted indan-1-ol systems for the prophylaxis or... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3316319